Anocca Appoints Martin Welschof to Board of Directors
SÖDERTÄLJE, SWEDEN, 13 February 2024 – Anocca AB, a leading TCR-T[1] cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors.
Martin Welschof is currently CEO of BioInvent International AB, a listed clinical-stage cancer immunotherapy company. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld.
